Tags : LegoChem Biosciences

Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates

Shots: LCB to receive $7.25M upfront, $404M as regulatory & commercial milestones and royalties on sales of ADCs product. Takeda licenses rights for LCB’s ConjuAll technology including linker and conjugation platform to develop & commercialize targetted immune-oncology therapies for three targets The focus of the collaboration is to utilize LCB’s ADC technology including linker and […]Read More